Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
Authors:
Open Access
- 4 February 2025
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 74 (3) , 1-11
Abstract
Combination therapy with nivolumab and ipilimumab for advanced renal cell carcinoma (RCC) may cause immune-related myocarditis; however, its incidence in this cancer type and regimen remains unknown. At our institution, we measure biomarkers, such as high-sensitivity Troponin (hsTn), and perform electrocardiograms (ECGs) and echocardiography before and every month after the initiation of this therapy, and the findings obtained and patients’ symptoms are continuously monitored by physicians and pharmacists. A retrospective survey was conducted on physiological and biochemical test findings and immune-related adverse events in patients with advanced RCC who received combination therapy with nivolumab and ipilimumab between October 1, 2018 and December 31, 2023. Patients suspected of having myocarditis consulted with cardiologists. Myocarditis due to this therapy was detected in 5 of the 86 patients (5.8%) assessed using the European Society of Cardiology 2022 guidelines. There were no fatal symptoms or death due to myocarditis. The median time to the onset of myocarditis was 25 days (21–86 days). The early detection of myocarditis caused by this therapy requires the monitoring of changes by periodically measuring hsTn and other cardiac markers and performing ECGs and echocardiography from the early stages of administration through to the end of treatment. In addition to checking symptoms, if these abnormalities are detected and myocarditis is suspected, prompt collaboration with cardiologists is recommended. Our management strategy of care by a onco-cardiology team may contribute to the early diagnosis and treatment of myocarditis.Keywords
This publication has 39 references indexed in Scilit:
- Routine Electrocardiogram Screening and Cardiovascular Disease Events in AdultsJAMA Internal Medicine, 2024
- Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced MyocarditisJACC: Cardiooncology, 2022
- Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditisArchives of Cardiovascular Diseases, 2022
- Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful managementUrology Case Reports, 2021
- Cardiovascular Magnetic Resonance in Nonischemic Myocardial InflammationJACC, 2018
- Fatal Toxic Effects Associated With Immune Checkpoint InhibitorsJAMA Oncology, 2018
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateEuropean Journal of Cancer, 2018
- Myocarditis in Patients Treated With Immune Checkpoint InhibitorsJACC, 2018
- Assessment of left ventricular ejection fraction may invalidate the reliability of EuroSCOREEuropean Journal of Cardio-Thoracic Surgery, 2006
- Visual estimation versus quantitative assessment of left ventricular ejection fraction: A comparison by cardiovascular magnetic resonance imagingAmerican Heart Journal, 2005